In “proof-of-concept” data, we show indeed that a dual p300/BRD4 inhibitor NEO273452,53 was superior to p300 or BRD4 inhibitors alone in killing T-ALL cells, paving way for future evaluation of NEO2734 in T-ALL. This evidence concerns the gene EP300 and acute lymphoblastic leukemia.